Seroatlas · Human Serome Atlas

AKT2

RAC-beta serine/threonine-protein kinase

Also known as: AKT2_HUMAN, PKBbeta

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
P31751
Gene
AKT2
Ensembl
ENSG00000105221
Chromosome
19
Canonical length
481 aa
Protein class
Cancer-related genes, Disease related genes, Enzymes, Human disease related genes, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins
Subcellular location
Nucleoplasm,Vesicles,Cytosol

OverviewNCBI Gene

This gene is a putative oncogene encoding a protein belonging to a subfamily of serine/threonine kinases containing SH2-like (Src homology 2-like) domains, which is involved in signaling pathways. The gene serves as an oncogene in the tumorigenesis of cancer cells For example, its overexpression contributes to the malignant phenotype of a subset of human ductal pancreatic cancers. The encoded protein is a general protein kinase capable of phophorylating several known proteins, and has also been implicated in insulin signaling. [provided by RefSeq, Nov 2019]

Canonical amino-acid sequenceUniProt

481 residues, UniProt reviewed canonical sequence.

>P31751|AKT2
     1  MNEVSVIKEG WLHKRGEYIK TWRPRYFLLK SDGSFIGYKE RPEAPDQTLP PLNNFSVAEC
    61  QLMKTERPRP NTFVIRCLQW TTVIERTFHV DSPDEREEWM RAIQMVANSL KQRAPGEDPM
   121  DYKCGSPSDS STTEEMEVAV SKARAKVTMN DFDYLKLLGK GTFGKVILVR EKATGRYYAM
   181  KILRKEVIIA KDEVAHTVTE SRVLQNTRHP FLTALKYAFQ THDRLCFVME YANGGELFFH
   241  LSRERVFTEE RARFYGAEIV SALEYLHSRD VVYRDIKLEN LMLDKDGHIK ITDFGLCKEG
   301  ISDGATMKTF CGTPEYLAPE VLEDNDYGRA VDWWGLGVVM YEMMCGRLPF YNQDHERLFE
   361  LILMEEIRFP RTLSPEAKSL LAGLLKKDPK QRLGGGPSDA KEVMEHRFFL SINWQDVVQK
   421  KLLPPFKPQV TSEVDTRYFD DEFTAQSITI TPPDRYDSLG LLELDQRTHF PQFSYSASIR
   481  E

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against AKT2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Cell surface
Secreted
No
Transmembrane segments
0
Mean surface accessibility (rSASA)
0.29
Highest tissue expression
111 nTPM

Expression across tissuesHPA

Tissue

  • tongue: 111 nTPM
  • thyroid gland: 94 nTPM
  • skeletal muscle: 92 nTPM
  • cerebellum: 88 nTPM
  • adipose tissue: 59 nTPM
  • parathyroid gland: 55 nTPM

Single-cell type

  • podocytes: 140 nCPM
  • bergmann glia: 137 nCPM
  • adipocytes: 123 nCPM
  • choroid plexus epithelial cells: 110 nCPM
  • hepatocytes: 101 nCPM
  • loop of henle epithelial cells: 99 nCPM

Immune cell

  • basophil: 5.9 nTPM
  • plasmacytoid DC: 4.9 nTPM
  • neutrophil: 4.1 nTPM
  • naive B-cell: 2.9 nTPM
  • classical monocyte: 2.7 nTPM
  • naive CD8 T-cell: 2.7 nTPM

Brain region

  • cerebellum: 143 nTPM
  • choroid plexus: 139 nTPM
  • cerebral cortex: 105 nTPM
  • white matter: 94 nTPM
  • medulla oblongata: 90 nTPM
  • amygdala: 87 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about AKT2.

Disease | AllUniProt

Conditions AKT2 is implicated in, by any mechanism.

  • Type 2 diabetes mellitus (T2D) MIM:125853
  • Hypoinsulinemic hypoglycemia with hemihypertrophy (HIHGHH) MIM:240900

Disease | GeneticClinVar

2 pathogenic / likely-pathogenic of 255 ClinVar records.

Conditions with pathogenic or likely-pathogenic variants.

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
0.42
gnomAD pLI
0.64
gnomAD missense Z
2.41
DepMap mean gene effect
-0.1
DepMap dependency class
selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 9% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of AKT2 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads AKT2 as an antibody target. Whether an autoantibody or antibody against AKT2 could matter depends on whether native AKT2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

AKT2 is annotated at the cell surface, where native AKT2 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label AKT2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/AKT2. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

© 2026 · Seroatlas, Discover Oregon LLC · Terms of use

Loading the interactive Seroatlas protein explorer...